六肽对兔血小板聚集活性的影响

目的研究六肽对兔血小板聚集活性的影响。方法采集健康家兔颈动脉血,以枸橼酸钠抗凝,用比浊法测其血小板在不同诱导剂诱导下聚集率。结果 1×10 5mol.L 1六肽,对兔ADP、花生四烯酸(AA)和凝血酶诱导的血小板聚集的抑制率分别为(66.22±1.40)%,(67.94±2.32)%和(58.18±4.67)%。六肽抑制兔ADP、AA和凝血酶诱导的血小板聚集的IC50分别为3.24×10 6mol.L 1,1.32×10 6mol.L 1和7.24×10 6mol.L 1。结论六肽在体外具有抑制兔血小板聚集的作用。     

Cardiovascular effects induced by N-(4'-dihydro)-piperoylthiomorpholine in normotensive rats

Objectives We have tested the cardiovascular effects of N‐(4′‐dihydro)‐piperoylthiomorpholine (LASSBio 365) on rats using an in‐vivo and in‐vitro approach. Methods LASSBio 365 (0.025, 0.05, 0.1, 0.25, 0.5 or 1 mg/kg, randomly injected) was administered to conscious unrestrained rats and the mean arterial pressure and heart rate were measured. The effects of LASSBio 365 (3 × 10^?6–3 × 10^?4m ) on rat isolated aortic rings with and without endothelium were investigated. Key findings LASSBio 365 induced a dose‐dependent decrease in mean arterial pressure and heart rate (ED50 = 158 ± 53 µg/kg). The effects evoked by LASSBio 365 (0.5 mg/kg) were inhibited by pretreatment with atropine. In anaesthetized rats, electrocardiogram recordings revealed second/third degree sinoatrial and atrioventricular blockade induced by the compound, which were completely inhibited after cardiac muscarinic blockade or cervical bilateral vagotomy. In rat isolated aortic rings, LASSBio 365 (3 × 10^?6–3 × 10^?4m ) was capable of antagonizing the contractile effects induced by phenylephrine (1 µm ) or KCl (80 mm ) (IC50 = 107 ± 6; 92 ± 6 µm , respectively). This effect was not inhibited after removal of the vascular endothelium (IC50 = 84 ± 4; 92 ± 10 µm , respectively). LASSBio 365 (10^?6–10^?4m ) antagonized CaCl₂‐induced contractions in a concentration‐dependent manner. Furthermore, LASSBio 365 (98 µm ) inhibited contractions produced by noradrenaline (1 µm ), but not those induced by caffeine (20 mm ). Conclusions These results suggested that LASSBio 365 produced negative chronotropism and reduced peripheral resistance that were probably due to the stimulation of cardiac muscarinic pathways. Peripheral vasodilation was probably linked to voltage‐dependent Ca²⁺‐channel blockade and/or specific inhibition of Ca²⁺ release from noradrenaline‐sensitive intracellular stores.     

Differential proteomic analysis of platelets suggested target-related proteins in rabbit platelets treated with Rhizoma Corydalis

Context: Corydalis yanhusuo W.T. Wang (Papaveraceae) (Rhizoma Corydalis) showed inhibitory effects on rabbit platelet aggregation induced by ADP, thrombin (THR) or arachidonic acid (AA).

Objective: This study separates and identifies the possible target-related platelet proteins and suggests possible signal cascades of RC antiplatelet aggregation.

Materials and methods: Based on comparative proteomics, the differentially expressed platelet proteins treated before and after with 50?mg/mL RC 90% ethanol extract (for 15?min at 37?°C) were analyzed and identified by two dimensional gel electrophoresis (2-DE) and MALDI-TOF-MS/MS. To further verify the possible signalling pathways of RC antiplatelet aggregation function, the concentration of calcium (Ca²⁺) was measured by Fura-2/AM fluorescence (Ex 340/380?nm, Em 500?nm) (RC final concentrations of 0.0156–0.1563?mg/mL), the levels of P-selectin and cyclic guanosine monophosphate (cGMP) were quantified by ELISA (OD. 450?nm) (RC final concentrations of 0.0156–1.5625?mg/mL), and the 5-hydroxytryptamine (5-HT) level was measured using ortho-phthalaldehyde (OPT) fluorescence (Ex 340?nm, Em 470?nm) (RC final concentrations of 0.3125–1.5625?mg/mL).

Results: The expression of 52 proteins were altered in rabbit platelets after the treatment and the MALDI-TOF-MS analysis indicated that those proteins include 12 cytoskeleton proteins, 7 cell signalling proteins, 3 molecular chaperone proteins, 6 proteins related to platelet function, 16 enzymes and 7 other related proteins. Furthermore, RC extract could decrease the levels of 5-HT [inhibition rate of 96.80% (p?vs. THR-activated group) treated with 0.7813?mg/mL of RC], Ca^2+?[172.73?±?5.07 to 113.56?±?5.46?nM (p?vs. THR-activated group) treated with 0.0313?mg/mL of RC] and P-selectin [13.48?±?0.96?ng/3?×?10⁸ to 11.64?±?0.17?ng/3?×?10⁸ (p?vs. THR-activated group) treated with 0.0156?mg/mL of RC], and increase in cGMP level [38.93?±?0.57 to 50.26?±?4.05?ng/3?×?10⁸ (p < 0.05, vs. THR-activated group) treated with 1.5165?mg/mL of RC] in ADP (10?μmol/L), THR (0.25?u/mL) or AA-(0.205?mmol/L) activated rabbit platelets.

Discussion and conclusion: The present study indicated that P2Y12 receptor might be one of the direct target proteins of RC in platelets. The signal cascades network of RC after binding with P2Y12 receptor is mediating Gαi proteins to activate downstream signalling pathways (AC and/or PI3K signalling pathways) for the inhibition of platelet aggregation.     

异钩藤碱对血小板聚集与血栓形成的抑制作用

目的研究异钩藤碱(isorhynchophylline,Isorhy)对血小板聚集与血栓形成的影响,并探讨其机制。方法以比浊法测定Isorhy体外给药对大鼠血小板聚集的影响;采用动-静脉旁路血栓形成法制作大鼠血栓模型,观察Isorhy对血栓形成的作用;以放免法测定Isorhy对ADP作用下cAMP含量的影响。结果Isorhy0.65mmol.L-1和1.30mmol.L-1对ADP(1.5×10-5mol.L-1)和凝血酶(thrombin,Thr,3U.ml-1)诱导的大鼠血小板聚集均有抑制作用(P<0.01)。静脉注射Isorhy10mg.kg-1和5mg.kg-1可明显降低大鼠血栓形成湿重(P<0.01)。Isorhy0.33~1.30mmol.L-1可升高ADP作用后的血小板cAMP浓度(P<0.01)。结论Isorhy明显抑制血小板聚集与大鼠血栓形成,其抗ADP所致血小板聚集的作用机制至少部分地与升高cAMP水平有关。     

Bakkenolide G,a Natural PAF-receptor Antagonist

Because platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) participates in many physiopathological responses, including inflammatory reaction, endotoxic shock, allergic diseases and platelet aggregation, PAF-receptor antagonists are important in the treatment of these diseases. A biologically active compound, bakkenolide G, extracted from the plant Petasites formosanus selectively and concentration-dependently inhibited PAF-induced platelet aggregation and ATP release. The IC50 of bakkenolide G for PAF (2 ng mL^?1)-induced platelet aggregation was 5.6 ± 0.9 μm . Bakkenolide G also concentration-dependently inhibited PAF-induced intracellular signal transductions, including thromboxane B₂ formation, and increased intra-cellular calcium concentration and phosphoinositide breakdown without affecting those caused by thrombin (01 units mL^?1), collagen (10 μg mL^?1), arachidonic acid (100 μm ) and U46619 (1 μm ). Bakkenolide G shifted the concentration-response curves of PAF-induced platelet aggregation parallel to the right; the Schild plot slope and the pA₂ value were 1.31 ± 0.31 and 6.21 ± 0.75, respectively. Moreover, bakkenolide G concentration-dependently competed with [³H]PAF binding to platelets, with an IC50 value of 2.5 ± 0.4 μm . These data strongly indicate that bakkenolide G is a specific PAF-receptor antagonist as an antiplatelet aggregatory agent.     

Ex-vivo and In-vivo Antithrombotic Effect of Triflavin,an RGD-containing Peptide

Abstract— Triflavin, an Arg-Gly-Asp-containing snake venom peptide, inhibits platelet aggregation through the blockade of fibrinogen binding to the activated platelets. It binds to fibrinogen receptors associated with the glycoprotein IIb/IIIa complex with a K_d value of 7 × 10^?8 m. In this study, we found that ¹²⁵I-triflavin reached the maximal binding to human platelets within 5 min at 25°C. In addition, when triflavin was intravenously administered at 1·0 mg kg^?1 to rabbits, it reversibly impaired the platelet aggregation of platelet-rich plasma caused by ADP (20 μm) ex-vivo over 30 min. The platelet counts of the experimental rabbits remained unchanged. Triflavin was effective in reducing the mortality of ADP-induced acute pulmonary thromboembolism in mice when administered intravenously at a dose of 2 μg g^?1. Therefore, triflavin was proven to be an effective antithrombotic agent in preventing ADP-induced acute pulmonary thromboembolism in mice and impairing reversibly the platelet function of rabbits when given intravenously.     

钩藤碱对家兔血小板聚集及胞浆游离钙离子浓度的影响

目的 研究钩藤碱(Rhy)对兔血小板细胞内游离钙离子浓度及血小板聚集的影响.方法 56只雄性家兔的血样随机分为正常对照组,阿司匹林0.85,1.69和2.78 mmol·L-1组,Rhy 0.33,0.65和1.30 mmol·L-1组.Born法测定血小板聚集率,双波长Fura-2荧光分光光度法测定血小板胞浆游离钙离...     

Dual Inhibition of Platelet-activating Factor and Arachidonic Acid Metabolism by Ajmaline and Effect on Carrageenan-induced Rat Paw Oedema

Abstract— The effects of ajmaline on human platelet aggregation, arachidonate metabolism and platelet activating factor (PAF)-induced lethality in rabbits were examined. Platelet aggregation induced by several stimuli (ADP, collagen, and PAF) was inhibited by increasing concentrations of ajmaline. The potency of ajmaline was higher when PAF was employed as stimulating agent in comparison with other agonists (IC50 70, 270 and 380 μm for PAF, ADP and collagen, respectively) whereas ajmaline had no effect against arachidonic acid-induced aggregation. In contrast however, ajmaline inhibited arachidonate metabolism by platelet homogenates. The formation of both thromboxane A₂ and 12-hydroxy-eicosatetraenoic acid was inhibited by ajmaline with comparable potencies. Pretreatment of rabbits with ajmaline (50 mg kg^?1) completely abolished the lethal effects of PAF (11 μg kg^?1) given intravenously (P < 0·001). In addition, ajmaline at doses ranging from 50 to 100 mg kg^?1 inhibited carrageenan-induced rat paw oedema (P < 0·001). In this test ajmaline was three times more potent than aspirin. In the light of these results we conclude that ajmaline, a known anti-arrhythmic agent is a PAF antagonist and a dual inhibitor of platelet cyclo-oxygenase and lipoxygenase enzymes with anti-inflammatory properties.     

Modification of Ca2+ Metabolism in the Rabbit Aorta as a Mechanism of Spasmolytic Action of Warifteine,a Bisbenzylisoquinoline Alkaloid Isolated from the Leaves of Cissampelos sympodialis Eichl. (Menispermaceae)

The regulation of intracellular Ca²⁺ as a mechanism of spasmolytic activity of a bisbenzylisoquinoline alkaloid, warifteine, isolated from the leaves of Cissampelos sympodialis, Eichl (Menispermaceae) was studied in the rabbit aorta. Warifteine (pD'₂ 4.12 ± 0.09) similar to verapamil (pD'₂ 6.89 · 0.05) antagonized, in a noncompetitive and reversible manner, KCl-induced contractions, mediated by Ca²⁺ entry through voltage-operated channels. Noradrenaline-induced sustained contractions mediated by Ca²⁺ entry through receptor-operated channels were also inhibited by warifteine (IC50 6.03 × 10^?5 m ) and the standard agent sodium nitroprusside (IC50 1.9 × 10^?8 m ). In Ca²⁺-free medium, the alkaloid reduced the intracellular Ca²⁺-dependent transient contraction to noradrenaline by inhibiting the release of Ca²⁺ (IC50 2.6 × 10^?5 m ) from the stores and the refilling (IC50 1.9 × 10^?5 m ) of the intracellular stores. The standard agent, procaine, also inhibited the release of Ca²⁺ (IC50 3.2 × 10^?5 m ) but had no significant effect on Ca²⁺ uptake into the stores. Warifteine failed to affect intracellular Ca²⁺ stores sensitive to caffeine, while procaine inhibited (IC50 7.9 × 10^?4 m ) the release of Ca²⁺ from these stores. The results indicate that warifteine may cause muscle relaxation by inhibiting Ca²⁺ channels and by modifying the intracellular Ca²⁺ stores sensitive to noradrenaline.     

Dual Inhibitory Action of ATP on Adrenergic Neuroeffector Transmission in Rabbit Pulmonary Artery

The aim of this study was to determine whether the inhibitory action of ATP on sympathetic neuroeffector transmission in the isolated pulmonary artery is due to ATP itself or one of its dephosphorylated breakdown products, ADP, AMP or adenosine. Furthermore, the mechanism of the inhibitory action was investigated. ATP (10^?6?3 × 10^?4 M), the degradation-resistant ATP-analogue, β, γ-methylene-5′-triphosphate (10^?5?3 × 10^?4 M), ADP (10^?6?3 × 10^?4 M), AMP (10^?5?3 × 10^?4 M), adenosine (10^?5?3 × 10^?4 M) and 2-chloroadenosine (10^?7?3 × 10^?4 M) reduced the contractions evoked by field-stimulation. This was also the case for prostaglandin E₂ (3 × 10^?9?3 × 10^?7 M), while prostaglandin F_2α(1.4 × 10^?8 M) slightly augmented the neurogenic response. The time course of the inhibitory effect of purinergic compounds on the stimulation evoked contractions was studied. In the case of ATP and ADP the inhibition was biphasic: an initial marked block (1 min. after drug addition) which in the continued presence of either compound recovered partially 10 min. later and then remained almost constant for another 90 min. The other purinergic agents caused a monophasic reduction. In the presence of indomethacin (5 × 10^?5 M), ATP and ADP also reduced the neurogenic contractions in a monophasic manner. Indomethacin did not alter the β,γ-methylene-5′-triphosphate-induced inhibition. Dilazep (3 × 10^?6 M) plus deoxycoformycin (3.6 × 10^?6 M), augmented the inhibitory effect of ATP. In contrast, theophylline (5 × 10^?5 M) did not alter the effect of ATP. The inhibitory effect of ATP (10^?4 M) on stimulation-evoked contractions was inversely proportional to the extracellular Ca²⁺ concentration (0.3–5.2 mM) and to frequency of stimulation (3–15 Hz). These results suggest that ATP initially causes a presynaptic inhibition of noradrenaline release evoked by field-stimulation. This phase I block is probably mainly due to an ADP-mediated short-lasting release of prostaglandins of the E type. The continuous inhibition (phase II) is probably due to ATP and its metabolites, possibly mainly adenosine. The phase II inhibition may possibly involve a decreased entry of Ca²⁺ into adrenergic nerve terminals during depolarization.     

ZD9583, an Orally Effective Thromboxane A2 Synthase Inhibitor and Receptor Antagonist with a Sustained Duration of Action in Rat and Dog

The thromboxane A₂ (TXA₂) synthase inhibitory activity and the TXA₂ receptor (TP-receptor) blocking action of ZD9583 ((4Z)-6-[(2S,4S,5R)-2-(1-[2-cyano-4-methylphenoxy]-1-methylethyl)-4-(3-pyridyl)-1,3-dioxan-5-yl]hex-4-enoic acid) has been evaluated in-vitro by use of whole blood and platelets from man, and ex-vivo by use of platelets and whole blood from rats and dogs. ZD9583 caused concentration–dependent inhibition of human platelet microsomal TXA₂ production with an IC50 of 0.017 ± 0.003 μm; this inhibition was associated with an increase in prostaglandin E₂ (PGE₂) and prostaglandin F_2α (PGF_2α) formation. ZD9583 also inhibited collagen-stimulated TXA₂ synthesis in whole blood from man, rat and dog giving IC50 values of 0.027 ± 0.005, 0002 ± 0.006 and 0.013 ± 0.01 μm, respectively. The drug did not modify platelet cyclooxygenase activity as inhibition of thromboxane B₂ (TXB₂) formation was associated with a concomitant increased synthesis of prostaglandin D₂ (PGD₂), PGE₂ and PGF_2α. ZD9583 had little effect on cultured human umbilical vein endothelial cell prostacyclin synthase giving an IC50 of 24.2 ± 4.9 μm. In-vitro ZD9583 caused concentration-dependent inhibition of U46619-induced aggregation responses of platelets from man, rat and dog, yielding apparent log A₂ values of 8.7 ± 0.12, 8.8 ± 0.2 and 9.3 ± 0.2, respectively. The drug was selective; at concentrations up to 100 μm it did not affect 5-hydroxytryptamine or the primary phases of adenosine diphosphate and adrenaline-induced aggregation. ZD9583 (100 μm) did not, furthermore, modify the platelet inhibitory effects of PGD₂, prostaglandin E₁ (PGE₁) and prostacyclin. Oral administration of ZD9583 (3–10 mg kg^?1) to both rats and dogs caused dose-dependant inhibition of collagen-stimulated TXA₂ production ex-vivo which persisted for up to 12 h. The drug also caused profound TXA₂ receptor blockade in both species for in excess of 12-h after an oral dose of 3 mg kg^?1. ZD9583 (3 mg kg^?1, p.o.), when administered to dogs over a five-day period at 12 h intervals, did not cause either tachyphylaxis or an accumulation of effect. We conclude that ZD9583 is a potent, selective, orally active thromboxane synthase inhibitor and TXA₂ receptor antagonist.     

Mechanism of Action of p-Chlorobiphenyl on the Inhibition of Platelet Aggregation

p-Chlorobiphenyl (1–50 μm ) concentration-dependently inhibited the aggregation and release reaction of rabbit washed platelets induced by arachidonic acid and collagen, but not those induced by platelet-activating factor (PAF), U46619 and thrombin. The IC50 values of p-chlorobiphenyl on the arachidonic acid and collagen-induced platelet aggregation were 2.9 ± 0.5 and 12.8 ± 2.3 μm , respectively. The formation of both platelet thromboxane B₂ and prostaglandin D₂ caused by arachidonic acid was inhibited by p-chlorobiphenyl concentration-dependently. In myo-[³H]inositol-labeled and fura-2-loaded platelets, [³H]inositol monophosphate generation and the rise in intracellular Ca²⁺ stimulated by arachidonic acid were inhibited by p-chlorobiphenyl. In human platelet-rich plasma, p-chlorobiphenyl and indomethacin prevented the secondary aggregation and blocked ATP release from platelets induced by adenosine 5′-diphosphate and adrenaline without affecting the primary aggregation. It is concluded that p-chlorobiphenyl may be a cyclo-oxygenase inhibitor and its antiplatelet action is mainly due to the inhibition of thromboxane formation.     

A pre-junctional action of 5-hydroxytryptamine and methysergide on noradrenergic nerves in dog isolated saphenous vein

Electrical stimulation (2 Hz for 2 min) of dog isolated saphenous vein strips pre-incubated with tritiated noradrenaline increased the overflow of tritium of which about 80% was noradrenaline. 5-Hydroxytryptamine (5-HT; 1·0 × 10^?9-1·0 × 10^?7 mol litre^?1) and methysergide (3·0 × 10^?8-3·0 × 10^?8 mol litre^?1) inhibited the induced overflow of total tritium by a maximum of 78 ± 4% and 47 ± 7% respectively (mean ± s.e. mean, n = 6 for each). Methysergide was about 30 times less potent than 5-HT and the maximum inhibition obtained was less than with 5-HT. Both compounds inhibited electrically-induced contractions and overflow of tritiated noradrenaline. Their inhibitory actions on tritium overflow were little affected by phentolamine (1·0 × 10^?8 mol litre^?1) or cyproheptadine (1·0 × 10^?8 mol litre^?1), nor was the inhibitory effect of methysergide on electrically induced contractions antagonized by atropine, mepyramine, cimetidine or propranolol. The findings suggest that the prejunctional inhibitory effect of methysergide may be mediated via stimulation of a 5-HT receptor which, unlike the D-receptor, is not blocked by cyproheptadine. The possibility that the pre-junctional 5-HT receptor in the dog saphenous vein is the same as the post-junctional receptor in this preparation is discussed.     

In-vitro and Ex-vivo Inhibition of Blood Platelet Aggregation by Naftazone

Because of the considerable interest in the role of platelets and antiplatelet therapy in cardiovascular disease, including the aggregation of platelets to each other during arterial thrombosis and atherogenesis, we have studied the effect of naftazone (Etioven), an original vasculotropic drug on platelet aggregation. Rat and human platelets were prepared and incubated in-vitro with different concentrations of naftazone. We found that naftazone inhibited both platelet secretion and aggregation in platelet-rich plasma (PRP) and washed platelets after stimulation with thrombin or ADP. Rats were also treated intraperitoneally for five days with various naftazone doses (0.125-10 mg kg^?1) and ex-vivo platelet aggregation compared, at various times after the last injection, with that of control animals. Inhibition by naftazone was dose-dependent in both PRP and isolated platelets. The inhibition was transient, a maximum value (～ 50%) being obtained about 3–6 h after the last injection, with a return to near-control values after 24 h. Naftazone also facilitated platelet deaggregation after in-vitro stimulation with thrombin or ADP. In another series of experiments, rats were treated intraperitoneally for five days with 10 mg kg^?1 of aspirin, ticlopidine, dipyridamole or naftazone. Platelets were prepared and tested for aggregation 90 min after the last injection. Thrombin-induced aggregation in PRP and washed platelets was significantly reduced after in-vivo treatment with ticlopidine and naftazone. Except for dipyridamole, all the drugs inhibited ex-vivo ADP-induced aggregation in PRP. In isolated platelet preparation, only naftazone induced a significant inhibition of ADP-or thrombin-stimulated aggregation. We conclude that naftazone inhibits platelet aggregation in-vitro and ex-vivo.     

Inhibition of platelet aggregation by 5′-nucleotidase purified from Trimeresurus gramineus snake venom

By means of DEAE-Sephadex A-50 column chromatography and gel filtrations on Sephadex G-75, Sephacryl S-300 and Sephadex G-100, successively, a potent 5′-nucleotidase was purified from Trimeresurus gramineus venom. The venom 5′-nucleotidase is a single polypeptide chain and homogeneous as judged by SDS-polyacrylamide gel electrophoresis. It is a thermostable glycoprotein consisting of 589 amino acid residues. Its molecular weight was estimated to be 74,000 by SDS-polyacrylamide gel electrophoresis. It possessed nucleotidase activities toward adenosine monophosphate and adenosine diphosphate. The specific activities toward AMP and ADP were 504 ± 28 and 101 ± 8 μg P_i/min per mg, respectively. Pre-incubation of this venom's 5′-nucleotidase with ADP resulted in the cleavage of ADP and formation of adenosine. The 5′-nucleotidase activity was inhibited by EDTA. Both Zn²⁺ and Co²⁺ reversed the inhibitory effect of EDTA.In rabbit platelet-rich plasma, it inhibited completely the ADP (2 × 10^-5 g/ml)-induced platelet aggregation. It also inhibited the platelet aggregations induced by sodium arachidonate (100 μM), collagen (20 μg/ml) and ionophore A-23187 (5 μM). In rabbit platelet suspensions, it inhibited the platelet aggregation induced by ADP (2 × 10^-5 g/ml), sodium arachidonate (100 μM) and low concentration of thrombin (0.03 U/ml). The collagen (20 μg/ml)- and ionophore A-23187 (5 μM)-induced platelet aggregations were not affected significantly by this venom 5′-nucleotidase. In ADP-refractory platelet-rich plasma, the venom 5′-nucleotidase inhibited the platelet aggregations induced by collagen (20 μg/ml) or sodium arachidonate (100 μM). The venom 5′-nucleotidase showed a more pronounced inhibitory effect on sodium arachidonate-induced platelet aggregation than creatine phosphate/creatine phosphokinase and apyrase did. No lactate dehydrogenase was released by this venom 5′-nucleotidase, indicating that no platelet lysis occurred. It is concluded that removal of ADP, which is released by these platelet aggregation inducers, and the subsequent accumulation of adenosine are responsible for the inhibitory effect of the venom 5′-nucleotidase on platelet aggregations.     

盐酸非洛普对人和兔血小板聚集的影响

用比浊法和放射免疫法分别测定盐酸非洛普对兔和人血小板聚集及兔血栓素Ａ２（ＴＸＡ２）和动脉壁前列环素（ＰＧＩ２）含量的影响。盐酸非洛普呈剂量依赖性抑制ＡＤＰ（ＩＣ５０＝５．８×１０－４ｍｏｌ·Ｌ－１）和ＡＡ诱导的兔血小板聚集。对ＡＤＰ和Ａｄｒ诱导的人血小板聚集亦有明显抑制作用且呈剂量依赖性，ＩＣ５０值分别为１．２和１．３×１０－４ｍｏｌ·Ｌ－１。盐酸非洛普短期应用（８ｍｇ·ｋｇ－１ｉｖｔｉｄ×２ｄ）明显抑制ＡＤＰ和ＡＡ诱导的兔血小板聚集及ＴＸＢ２的产生和释放，对兔动脉壁和血浆６－ｋｅｔｏ－ＰＧＦ１α含量无显著影响。研究结果表明，盐酸非洛普抗血小板聚集作用与其抑制血小板ＴＸＡ２合成和释放有关，亦可能与其α２受体阻断作用有关。     

Some neurochemical properties of a new antidepressant,bupropion hydrochloride (Wellbutrin™)

Bupropion is a novel antidepressant agent. In the present study, an attempt was made to gain some insight into the mechanism of the drug's antidepressant activity. In vitro studies revealed that bupropion was a weak, competitive inhibitor of norepinephrine (NE) uptake into rat hypothalamic synaptosomes and of dopamine (DM) uptake into rat striatal synaptosomes, having IC50 values of 6.5 ± 0.6 × 10^?6 M and 3.4 ± 0.4 × 10^?6 M, respectively. At 1 × 10^?5 M, the drug produced a 20 ± 3% inhibition of serotonin (5-HT) uptake into rat hypothalamic synaptosomes. The drug was also a weak inhibitor of the ATP-Mg⁺² stimulated uptake of NE and DM into synaptic vesicles of whole rat brain, having IC50 values of 3.3 × 10^?5 M and 6.0 × 10^?5 M, respectively. Bupropion had no dose-dependent effect on the spontaneous release of NE, DM, and 5-HT from these synaptosomal preparations in concentrations as high as 1 × 10^?4 M. Brain monoamine oxidase (MAO) activity in vitro was not affected by concentrations of the drug ranging from 10^?7 M to 10^?5 M. Bupropion was also without effect on brain MAO, 1 hr after i.p. doses in rats as high as 100 mg/kg. The ED50 value for bupropion necessary to inhibit the uptake of ³H-catecholamines by 50% into synaptosomes incubated in the serum from rats treated with the drug was 40 mg/kg i.p., while its ED50 value for antidepressant activity, as judged by the ability of bupropion to reverse the immobile posture of “helpless” rats, was 8 mg/kg i.p. These neurochemical properties of bupropion on uptake of biogenic amines and on MAO activity serve to distinguish it from other antidepressant drugs of the tricyclic and MAO inhibitor classes.     

Possible differences in α-adrenoceptors in rabbit ileum and spleen

In isolated tissues from reserpinized rabbits (5 mg kg^?1, i.m. 20 h before experiment) and in the presence of cocaine (3 × 10^?5 m ), corticosterone (2·8 × 10^?5 m ), tropolone (3 × 10^?5m ), propranolol (4 × 10^?6m ) and disodium EDTA (3 × 10^?5m ), the potency ratios (relative to (—)-noradrenaline) of (—)adrenaline, (—)-phenylephrine and (±)-methoxamine were (m ± s.e.) 203 ±0·13, 0·045 ± 0·003 and 0·0062 ± 0·0018 respectively in splenic strips and 1·77 ± 0·41, 0·093 ± 0·018 and 0·029 ± 0·004 respectively in isolated ileum. Although the pA₂ values for phentolamine and thymoxamine against (—)-noradrenaline in the two tissues were very similar there was a statistically significant difference when using yohimbine as the α-adrenoceptor blocking agent (pA₂ = 6·80 ± 0·30 in spleen; 5·60 ± 0·12 in ileum). These differences suggest that the α-adrenoceptor in the two tissues is not identical. The pA₂ value of phentolamine in rabbit ileum was not significantly different whether (—)-noradrenaline or (±)-methoxamine was used as agonist (7·91 ± 0·07 and 7·97 ± 0·06 respectively) while that of yohimbine was 5·56 ± 0·10 using (—)-noradrenaline and 6·19 ± 0·12 using (±)-methoxamine. In the light of this latter result and, considering the scatter of the experimentally determined values, there may be two α-adrenoceptors in rabbit ileum and either or both may not be identical in all respects to the α-adrenoceptor found in rabbit spleen.     

Characterization of a unique dihydropyrimidinone, ethyl 4-(4'-heptanoyloxyphenyl)-6-methyl-3,4-dihydropyrimidin-2-one-5-carboxylate, as an effective antithrombotic agent in a rat experimental model

Objectives To evaluate the potential of a novel dihydropyrimidinone, ethyl 4‐(4′‐heptanoyloxyphenyl)‐6‐methyl‐3,4‐dihydropyrimidin‐2‐one‐5‐carboxylate (H‐DHPM), as a calcium channel blocker, endowed with the ability to inhibit platelet aggregation effectively. Methods In‐vitro and in‐vivo studies were conducted for the determination of antiplatelet activity using adenosine diphosphate (ADP), collagen or thrombin as inducers. Calcium channel blocking activity and nitric oxide synthase (NOS) activity were monitored. Lipopolysaccharide (LPS)‐mediated prothrombotic conditions were developed in rats to study the efficacy of H‐DHPM to suitably modulate the inflammatory mediators such as inducible NOS (iNOS) and tissue factor. The cGMP level and endothelial NOS (eNOS) expression were checked in aortic homogenate of LPS‐challenged rats pretreated with H‐DHPM. The effect of H‐DHPM on FeCl₃‐induced thrombus formation in rats was examined. Key findings The concentrations of H‐DHPM required to give 50% inhibition (IC50) of in‐vitro platelet aggregation induced by ADP, collagen or thrombin were 98.2 ± 2.1, 74.5 ± 2.3 and 180.7 ± 3.4 µm , respectively. H‐DHPM at a dose of 52.0 ± 0.02 mg/kg (133 µmol/kg) was found to optimally inhibit ADP‐induced platelet aggregation in‐vivo. The level of nitric oxide was found to be up to 9 ± 0.08‐fold in H‐DHPM‐treated platelets in‐vitro and 8.2 ± 0.05‐fold in H‐DHPM‐pretreated rat platelets in‐vivo compared with control. OH‐DHPM, the parent compound was found to be ineffective both in‐vitro and in‐vivo. H‐DHPM‐pretreated rats were able to resist significantly the prothrombotic changes caused by LPS by blunting the expression of iNOS, tissue factor and diminishing the increased level of cGMP to normal. H‐DHPM enhanced the eNOS expression in aorta of rats treated with LPS. H‐DHPM displayed synergy with antiplatelet activity of aspirin even at lower doses. H‐DHPM was found to inhibit the LPS‐induced platelet aggregation in younger as well as older rats. H‐DHPM exhibited the ability to markedly decrease FeCl₃‐induced thrombus formation in rats. Conclusions H‐DHPM has the attributes of a promising potent antiplatelet candidate molecule that should attract further study. H‐DHPM displayed antiplatelet activity both in vivo and in vitro, which was due partially by lowering the intraplatelet calcium concentration.     

Antiplatelet Effect of Gingerol Isolated from Zingiber officinale

The purpose of this investigation was to determine the antiplatelet mechanism of gingerol. Gingerol concentration-dependently (0·5–20 μm ) inhibited the aggregation and release reaction of rabbit washed platelets induced by arachidonic acid and collagen, but not those induced by platelet-activating factor (PAF), U46619 (9,11-dideoxy-9α,11 α-methano-epoxy-PGF_2α) and thrombin. Gingerol also concentration-dependently (0·5–10μ m ) inhibited thromboxane B₂ and prostaglandin D₂ formation caused by arachidonic acid, and completely abolished phosphoinositide breakdown induced by arachidonic acid but had no effect on that of collagen, PAF or thrombin even at concentrations as high as 300 μ m . In human platelet-rich plasma, gingerol and indomethacin prevented the secondary aggregation and blocked ATP release from platelets induced by adenosine 5′-diphosphate (ADP, 5 μ m ) and adrenaline (5 ä m ) but had no influence on the primary aggregation. The maximal antiplatelet effect was obtained when platelets were incubated with gingerol for 30 min and this inhibition was reversible. It is concluded that the antiplatelet action of gingerol is mainly due to the inhibition of thromboxane formation.